Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

New Drug For Postpartum Depression On The Horizon

XTALKS VITALS NEWS

Depression

Not long ago, postpartum depression was a nearly-unrecognized condition despite its prevalence in new mothers.

Tweetables from this article:

Tweet: #Postpartumdepression drug was able to relieve symptoms in 70 percent of patients http://ctt.ec/eX5I7+Postpartum depression drug was able to relieve symptoms in 70 percent of patients.

Tweet: Sage estimates that 10 to 15% of mothers are affected by #postpartumdepression http://ctt.ec/xbdLe+Sage estimates that 10 to 15% of mothers are affected by postpartum depression.

Share this!

July 13, 2016 | by Sarah Massey, M.Sc.

Biotech company Sage Therapeutics has announced that their experimental postpartum depression drug was able to relieve symptoms in 70 percent of patients. The drug was tested in a Phase II clinical trial, which found that severe symptoms of depression could be put into remission for a month.

While the initial results look promising, the study did contain a few limitations. For one, the sample size was only 21 patients, with no follow-up after 30 days of the study.

According to Sage, the drug was well-tolerated among participants and no serious adverse events were reported. The company has not released all study data however, instead choosing to save some for a future medical conference.

Not long ago, postpartum depression was a nearly-unrecognized condition despite its prevalence in new mothers. While reliable statistics on the prevalence of postpartum depression are hard to come by, Sage estimates that 10 to 15 percent of the 4 million mothers who give birth to live babies each year, are affected by the condition in some way.

The company’s experimental treatment – named SAGE-547 – is delivered intravenously, making it ideal for patients who are hospitalized as a result of severe depressive symptoms. According to Sage, the drug is an allosteric modulator which interacts with the GABA A receptor, a key component in signals propagated by neurotransmitters.

Ten of the 21 patients enrolled in the Phase II clinical trial were given SAGE-547, while the remaining 11 participants were given a placebo. Some patients experienced improvement in their symptoms as early as 24 hours after the drug was administered.



Using the standard HAM-D depression scoring system, the researchers found that seven out of ten women on the postpartum drug saw their condition go into remission within 60 hours of receiving the treatment. This was compared to one out of the 11 patients in the placebo arm of the study, who saw improvement.

After 30 days, all seven patients on SAGE-547 were doing well, compared to two patients receiving the placebo. While the drug has so far only been tested on a relatively small number of women, the results are nevertheless very encouraging for a historically difficult-to-treat patient group.

“This is potentially one of the most important clinical findings in the pharmacologic treatment of postpartum depression to date,” said primary investigator Samantha Meltzer-Brody, an associate professor and director of the UNC Perinatal Psychiatry Program. Sage plans to further investigate the postpartum depression drug by enrolling more patients in the clinical trial to determine the optimal dose. The company also plans to develop an oral form of the medication.


Keywords: Biotech, Depression, Clinical Trial


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.